Evidence map›Paper›PMID 25565775›Full record

ArticleDrug design, development and therapy2015

Synthesis and characterization of a novel chemically designed (Globo)3-DTPA-KLH antigen.

Mehdi Hajmohammadi, Seyed Davar Siadat, Masoud Ghorbani, Mehdi Shafiee Ardestani, Shahram Teimourian, Vahid Asgari, Reza Ahangari Cohan, Mostafa Hajmohammadi, Akram Hajmohammadi, Ramezan Behzadi and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Mehdi HajmohammadiDepartment of Research and Biotechnology, Pasteur Institute of Iran, Tehran, Iran.
Seyed Davar SiadatDepartment of Microbiology, Pasteur Institute of Iran, Tehran, Iran.
Masoud GhorbaniDepartment of Virology, Pasteur Institute of Iran, Tehran, Iran ; Department of Virology, University of Ottawa, Ottawa, ON, Canada.
Mehdi Shafiee ArdestaniDepartment of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Shahram TeimourianDepartment of Medical Genetics, Iran University of Medical Sciences, Tehran, Iran.
Vahid AsgariDepartment of Virology, Pasteur Institute of Iran, Tehran, Iran.
Reza Ahangari CohanDepartment of Virology, Pasteur Institute of Iran, Tehran, Iran.
Mostafa HajmohammadiDepartment of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Akram HajmohammadiFaculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Ramezan BehzadiLaboratory Animal Management of North Research Center, Pasteur Institute of Iran, Tehran, Iran.
Saied Rajab NezhadDepartment of Research and Development, Alhavi Pharmaceutical, Tehran, Iran.
Nabiollah Namvar AslPasteur Institute of Iran, Department of Animal Sciences, Karaj, Iran.
Pasteur Institute of Iran · IRTehran University of Medical Sciences · IRAhvaz Jundishapur University of Medical Sciences · IRIran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, many experiments have been conducted for the production and evaluation of anticancer glycoconjugated vaccines in developed countries and many achievements have been accomplished with Globo H derivatives. In the current experiment, a new chemically designed triplicate version of (Globo H)3-diethylenetriamine pentaacetic acid (DTPA)-KLH antigen was synthesized and characterized. Immunization with (Globo H)3-DTPA-KLH, a hexasaccharide that is a member of a family of antigenic carbohydrates that are highly expressed in various types of cancers conjugated with DTPA and KLH protein, induced a high level of antibody titer along with an elevated level of IL-4 in mice. Treatment of tumors with the collected sera from immunized mice decreased the tumor size in nude mice as well. None of the immunized mice illustrated any sign of tumor growth after injection of MCF-7 cells compared to the control animals. These findings, based on the newly presented structure of the Globo H antigen, lend exciting and promising evidence for clinical advancement in the development of a therapeutic vaccine in the future.

Indexed as

Adjuvants, ImmunologicAnimalsAntigens, Tumor-Associated, CarbohydrateCancer VaccinesDrug DesignFemaleHemocyaninsHumansMammary Neoplasms, ExperimentalMCF-7 CellsMiceMice, NudeMolecular StructurePentetic AcidAdjuvants, ImmunologicAntigens, Tumor-Associated, CarbohydrateCancer VaccinesGlobo-HHemocyaninskeyhole-limpet hemocyaninPentetic Acidbreast cancer(Globo H)3-DTPA-KLHglycoconjugate vaccines

Identifiers

PMID25565775
PMCPMC4278734
OpenAlexW2072586040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.